Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma

• Published in: Journal of endocrinological investigation Vol. 21; no. 6; pp. 358 - 364
• Main Authors: CHIEFARI, E, RUSSO, D, BRUNO, R, GIANNASIO, P, PONTECORVI, A, FILETTI, S, GIUFFRIDA, D, ZAMPA, G. A, MERINGOLO, D, ARTURI, F, CHIODINI, I, BIANCHI, D, ATTARD, M, TRISCHITTA, V
• Format: Journal Article
• Language: English
• Published: Milano Kurtis 01.06.1998
• Subjects: Adult; Biological and medical sciences; Carcinoma, Medullary - genetics; Child; Drosophila Proteins; Endocrinopathies; Female; General aspects. Associated endocrine diseases. Endocrine paraneoplasic syndromes; Heterozygote; Humans; Male; Medical sciences; Multiple Endocrine Neoplasia Type 2a - genetics; Multiple Endocrine Neoplasia Type 2b - genetics; Mutation; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases - genetics; Thyroid Neoplasms - genetics; Endocrinopathy; Human; Retinoblastoma gene; Thyroid diseases; Medullary carcinoma; Thyroid gland; Malignant tumor; Carcinogenesis; Genetic determinism; Multiple endocrine neoplasia type II; Protooncogene; Genetic disease
• ISSN: 0391-4097; 1720-8386
• DOI: 10.1007/BF03350771

Medullary thyroid carcinoma (MTC) may occur either as a sporadic or familial (FMTC) disease. Multiple endocrine neoplasia (MEN) type 2, inherited as an autosomal dominant disease, is characterized by coexistence of MTC with other endocrine neoplasia. Activating mutations of the RET proto-oncogene, involving the somatic or the germinal cell lineage, are found in both inherited and acquired forms. In this study, RET mutations were screened in 47 individuals either affected by MTC or belonging to families with hereditary MTC. Exons 10, 11, 13, 14, 15 and 16 of the RET gene were amplified by polymerase chain reaction and examined by DNA sequence and/or restriction enzyme analysis to detect mutations in purified amplicons. Six MEN 2A families with a germline mutation at codon 634, one FMTC family carrying a mutation at codon 618 and two MEN 2B families with a mutation at codon 918 were identified. In affected members of a MEN 2A family no known RET mutations were observed. Besides, we identified a germline mutation in a patient with apparently sporadic MTC and in two out of three sons, indicating the presence of a sporadic misclassified familial disease. In all of the families examined we were able to distinguish the affected vs unaffected (not at risk) members. A somatic mutation of codon 918 was detected in three out of ten patients with apparently sporadic MTC.